111 Inc ADR Dossier - Source-backed chat

111 Inc ADR

YINASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)0.73

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.42Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $30.1M

Shares Outstanding 8.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

111, Inc. is undergoing a strategic transition toward an asset-light, platform-driven business model by divesting self-operated subsidiaries and optimizing its fulfillment network. While this transition has improved fulfillment expense efficiency and driven growth in marketplace service revenues, it has also resulted in a severe contraction of net revenues (down 33.1% YoY in Q1 2026) and a return to operating losses. Furthermore, the company faces significant liquidity pressure due to a massive RMB 0.95 billion redemption obligation owed to legacy investors of its subsidiary, 1 Pharmacy Technology, alongside a reversal to negative operating cash flows in Q1 2026. Given intense competition from well-capitalized giants like JD Health and Alibaba Health, the company's path to sustainable profitability remains highly uncertain.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The revenue contraction accelerates as the company loses market share to JD Health and Alibaba Health. Operating losses widen further, and legacy investors demand immediate redemptions of the remaining RMB 0.95 billion obligation, triggering a severe liquidity crisis and potential Nasdaq listing compliance issues.

Base CaseCentral scenario

The company continues its asset-light transition, stabilizing quarterly revenues around RMB 2.2B to 2.5B. Marketplace service revenues grow at a double-digit rate, but overall operating margins remain depressed near break-even due to intense pricing pressure in the B2B pharmaceutical distribution market. Liquidity remains tight as cash is consumed by phased repayments to 1 Pharmacy Technology investors.

Bull CaseUpside scenario

Successful transition to a high-margin, asset-light warehouse partnership model that drives operating profitability and positive cash flow despite lower top-line revenues.

Scenarios reflect our research view at the research date.

Key Investment Merits

Successful expansion of the high-margin Marketplace (MP) service business, with service revenue up 24.7% YoY in Q1 2026.
Improved fulfillment efficiency, with fulfillment expenses dropping 34.6% YoY and representing 2.6% of net revenue in Q1 2026.
Strong growth in promotional product sales, which grew 70.2% YoY in Q1 2026.

Key Investment Risks

Severe top-line contraction, with Q1 2026 net revenues declining 33.1% YoY due to the divestiture of self-operated subsidiaries.
Substantial liquidity risk from RMB 0.95 billion in redemption obligations owed to 1 Pharmacy Technology investors.
Intense competitive pressure from dominant, well-capitalized rivals such as JD Health and Alibaba Health.
Reversal to negative operating cash flow, recording an RMB 214.7 million outflow in Q1 2026.

Thesis Invalidation Triggers

Failure to maintain the restructured repayment schedule with 1 Pharmacy Technology investors, leading to accelerated redemption demands.
A prolonged period of quarterly operating losses exceeding RMB 30 million.
Inability to maintain compliance with Nasdaq's minimum bid price or other listing requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.